Inferra AIResearch Tools

Inferra AI / Company / BNTX

BioNTech

BNTX · Health Care

Last earnings Aug 4, 2026

AI analysis

Q2 2026 · reported Aug 4, 2026

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

On May 7, 2026, our Management Board and Supervisory Board authorized a new share repurchase program pursuant to which we may purchase American Depositary Shares, or ADSs, each representing one ordinary share, in the amount of up to $1.0 billion until and including May 6, 2027.

During the three and six months ended June 30, 2026, we repurchased 1,693,056 ADSs under the program at an average price of $89.50 ( 77.85), for a total consideration of $151.6 million ( 131.8 million).

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

BioNTech Q2 2026 results

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

On May 7, 2026, our Management Board and Supervisory Board authorized a new share repurchase program pursuant to which we may purchase American Depositary Shares, or ADSs, each representing one ordinary share, in the amount of up to $1.0 billion until and including May 6, 2027.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

During the three and six months ended June 30, 2026, we repurchased 1,693,056 ADSs under the program at an average price of $89.50 ( 77.85), for a total consideration of $151.6 million ( 131.8 million).

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Security investments are debt instruments under our asset management policy that generate a return individually and independently of our core operating activities.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Strategy & priorities

Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Addressing these two challenges is the core of our strategy.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

We have pursued both strategic partnerships and corporate collaborations to partially fund our infectious disease global health programs and aim to continue to do so.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior year period, were primarily driven by the inclusion of CureVac operations acquired in late 2025, as well as expenses associated with BioNTech s global initiative on scaling processes and ERP infrastructure to strengthen operational execution.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

This was partly offset by cost reductions resulting from the execution of initiatives related to our pipeline prioritization and increased cost discipline.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Risks & headwinds

BioNTech Quarterly Report for the three and six months ended June 30, 2026 20 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OPERATING AND FINANCIAL REVIEW AND PROSPECTS Moderna Proceedings Germany Infringement Proceedings EP 949 and EP 565 In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

United Kingdom In August 2022, Moderna filed a lawsuit asserting Comirnaty s infringement of EP 949 and EP 565 against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, and Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Addressing these two challenges is the core of our strategy.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Such assessment takes into account the fact that there is an inherent risk of failure in pharmaceutical development and uncertainty of approvals that depend on external regulatory agencies opinions.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Substantially all of our contingent liabilities are subject to significant uncertainties and, therefore, determining the likelihood of a loss and or the measurement of any loss can be complex.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

SEC original ↗BioNTech — Earnings release (6-K exhibit)EX-99Aug 4, 2026

Documents

Earnings deck slides

0 decks with slide view

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BioNTech — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

47 documents

Earnings releases

11 documents

Presentations

10 documents

Transcripts

0 documents

No transcripts for BioNTech are held in this edition of the library.

Mentioned by

10 companies

Other tracked companies whose held documents mention BioNTech by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.